Stock News

Jones Collombin Investment Counsel Has Trimmed Stake in Pfizer (PFE) by $548,280 as Stock Value Declined; Omnicell Com (OMCL) Holding Has Lifted by Timpani Capital Management Llc

Pfizer Inc. (NYSE:PFE) Logo

Timpani Capital Management Llc increased its stake in Omnicell Inc Com (OMCL) by 25.42% based on its latest 2017Q4 regulatory filing with the SEC. Timpani Capital Management Llc bought 16,895 shares as the company’s stock declined 14.33% with the market. The institutional investor held 83,369 shares of the technology company at the end of 2017Q4, valued at $4.04M, up from 66,474 at the end of the previous reported quarter. Timpani Capital Management Llc who had been investing in Omnicell Inc Com for a number of months, seems to be bullish on the $1.77B market cap company. The stock decreased 0.44% or $0.2 during the last trading session, reaching $45.5. About 39,983 shares traded. Omnicell, Inc. (NASDAQ:OMCL) has risen 5.20% since May 24, 2017 and is uptrending. It has underperformed by 6.35% the S&P500.

Jones Collombin Investment Counsel Inc decreased its stake in Pfizer Inc (PFE) by 5.81% based on its latest 2017Q4 regulatory filing with the SEC. Jones Collombin Investment Counsel Inc sold 15,230 shares as the company’s stock declined 3.13% with the market. The institutional investor held 246,915 shares of the health care company at the end of 2017Q4, valued at $8.94M, down from 262,145 at the end of the previous reported quarter. Jones Collombin Investment Counsel Inc who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $210.35 billion market cap company. The stock decreased 0.03% or $0.01 during the last trading session, reaching $35.96. About 8.51 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 2.43% since May 24, 2017 and is uptrending. It has underperformed by 9.12% the S&P500.

Investors sentiment increased to 1.06 in 2017 Q4. Its up 0.10, from 0.96 in 2017Q3. It increased, as 51 investors sold PFE shares while 675 reduced holdings. 134 funds opened positions while 632 raised stakes. 4.07 billion shares or 0.28% more from 4.06 billion shares in 2017Q3 were reported. Dorsey & Whitney Tru Co Limited Liability Corp accumulated 1.16% or 173,855 shares. Artemis Inv Llp has invested 0.01% of its portfolio in Pfizer Inc. (NYSE:PFE). 123,930 were accumulated by Eidelman Virant. West Oak Limited Liability Com has 23,747 shares for 0.53% of their portfolio. Confluence Wealth Mngmt Limited Company accumulated 6,585 shares. Quantitative Investment Ltd Liability Company stated it has 0.2% of its portfolio in Pfizer Inc. (NYSE:PFE). Millennium Management Ltd Com reported 0.18% in Pfizer Inc. (NYSE:PFE). Manchester Capital Lc stated it has 29,821 shares. Kepos LP reported 0.42% stake. Miles Cap reported 0.86% of its portfolio in Pfizer Inc. (NYSE:PFE). Cheviot Value Mgmt Lc has invested 4.34% in Pfizer Inc. (NYSE:PFE). Fil Ltd holds 1.52% or 15.03 million shares in its portfolio. Smith Salley & Associates owns 0.75% invested in Pfizer Inc. (NYSE:PFE) for 115,253 shares. De Burlo Group holds 0.04% in Pfizer Inc. (NYSE:PFE) or 5,907 shares. Cadence Comml Bank Na holds 101,597 shares or 1.35% of its portfolio.

Since December 15, 2017, it had 0 insider buys, and 13 sales for $17.75 million activity. On Wednesday, February 28 HILL CHARLES H sold $986,292 worth of Pfizer Inc. (NYSE:PFE) or 26,779 shares. Dolsten Mikael had sold 69,699 shares worth $2.55M on Friday, March 9. $4.76M worth of stock was sold by READ IAN C on Tuesday, May 1. JOHNSON RADY A had sold 8,000 shares worth $296,560 on Friday, December 15. On Monday, February 26 SUSMAN SALLY sold $1.24 million worth of Pfizer Inc. (NYSE:PFE) or 33,368 shares. $64,679 worth of stock was sold by CORNWELL W DON on Monday, February 26.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on August, 7. They expect $0.75 EPS, up 11.94% or $0.08 from last year’s $0.67 per share. PFE’s profit will be $4.39 billion for 11.99 P/E if the $0.75 EPS becomes a reality. After $0.77 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -2.60% negative EPS growth.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Streetinsider.com which released: “Pfizer (PFE) Says FDA Granted Breakthrough Therapy Designation for Tafamidis for Treatment of Patients with …” on May 23, 2018, also 247Wallst.com with their article: “What to Look For in the Merck and Pfizer Reports Tuesday Morning” published on April 30, 2018, 247Wallst.com published: “How Much Pfizer Earnings Depend on a Few Brands” on May 01, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: Buy This Dip?” published on May 03, 2018 as well as Streetinsider.com‘s news article titled: “Pfizer (PFE) Begins a Phase 1/2 Study to Evaluate RSV Vaccine” with publication date: May 22, 2018.

Jones Collombin Investment Counsel Inc, which manages about $304.23M US Long portfolio, upped its stake in Magna Intl Inc (NYSE:MGA) by 22,290 shares to 156,000 shares, valued at $8.84M in 2017Q4, according to the filing. It also increased its holding in Thomson Reuters Corp (NYSE:TRI) by 103,175 shares in the quarter, for a total of 105,475 shares, and has risen its stake in Manulife Finl Corp (NYSE:MFC).

Among 22 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 12 Hold. Therefore 41% are positive. Pfizer had 79 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Thursday, October 13. UBS maintained Pfizer Inc. (NYSE:PFE) rating on Wednesday, November 1. UBS has “Buy” rating and $38.0 target. Piper Jaffray maintained the shares of PFE in report on Friday, August 28 with “Overweight” rating. The company was maintained on Monday, July 10 by Cowen & Co. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, January 31. The firm has “Hold” rating by Argus Research given on Wednesday, November 2. As per Tuesday, September 5, the company rating was maintained by BMO Capital Markets. The firm earned “Hold” rating on Wednesday, October 28 by S&P Research. The rating was maintained by Jefferies with “Hold” on Thursday, October 26. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Tuesday, June 14 by Jefferies.

Investors sentiment increased to 1.12 in Q4 2017. Its up 0.10, from 1.02 in 2017Q3. It is positive, as 14 investors sold OMCL shares while 72 reduced holdings. 27 funds opened positions while 69 raised stakes. 37.38 million shares or 0.77% more from 37.10 million shares in 2017Q3 were reported. Westfield Mngmt LP owns 677,682 shares for 0.25% of their portfolio. Snyder Management Lp stated it has 208,885 shares. 130,097 are held by Waddell Reed. First Comml Bank Of Omaha accumulated 0.07% or 25,420 shares. Bahl And Gaynor reported 0.03% stake. Synovus holds 0.02% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL) for 21,077 shares. Kornitzer Mngmt Ks holds 155,240 shares or 0.13% of its portfolio. Atlantic Trust Grp Incorporated holds 0.01% or 51,666 shares. 43,973 were reported by Millennium Mngmt Limited Liability Company. Riverhead Cap Mgmt Ltd Liability Co has 0.01% invested in Omnicell, Inc. (NASDAQ:OMCL) for 5,500 shares. Delta Asset Management Ltd Llc Tn owns 31 shares or 0% of their US portfolio. Usa Portformulas Corp holds 0.09% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL) for 7,502 shares. 1492 Mngmt Lc holds 16,878 shares or 0.64% of its portfolio. Parallax Volatility Advisers Lp reported 5,628 shares. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 50,443 shares.

More notable recent Omnicell, Inc. (NASDAQ:OMCL) news were published by: Prnewswire.com which released: “Omnicell Announces First Quarter 2018 Results” on April 26, 2018, also Globenewswire.com with their article: “Report: Developing Opportunities within Opexa Therapeutics, Federated National Holding, Hess Midstream Partners …” published on May 24, 2018, Gurufocus.com published: “Mariko Gordon Closes Positions in Red Robin, Natus Medical” on May 23, 2018. More interesting news about Omnicell, Inc. (NASDAQ:OMCL) were released by: Prnewswire.com and their article: “VitalConnect Announces Joe Lynch as Chief Marketing Officer” published on May 24, 2018 as well as Seekingalpha.com‘s news article titled: “Omnicell’s (OMCL) CEO Randall Lipps on Q1 2018 Results – Earnings Call Transcript” with publication date: April 27, 2018.

Since December 15, 2017, it had 0 buys, and 7 selling transactions for $1.81 million activity. PETERSMEYER GARY S also sold $25,544 worth of Omnicell, Inc. (NASDAQ:OMCL) shares. JOHNSTON DAN S had sold 11,284 shares worth $507,248 on Monday, April 16. $361,938 worth of Omnicell, Inc. (NASDAQ:OMCL) was sold by LIPPS RANDALL A. 13,286 shares valued at $617,524 were sold by Seim Robin Gene on Tuesday, May 15.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *